Cargando…
Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure
Darbepoetin alfa (DA) is a unique long-acting treatment for anaemia in patients with chronic renal failure (CRF). This study assessed the mean dose of DA to achieve and maintain haemoglobin (Hb) levels between 11 g/dl and 13 g/dl in CRF children aged 11 years to 18 years. This observational, prospec...
Autores principales: | André, Jean-Luc, Deschênes, Georges, Boudailliez, Bernard, Broux, Françoise, Fischbach, Michel, Gagnadoux, Marie-France, Horen, Benjamin, Lahoche-Manucci, Annie, Macher, Marie-Alice, Roussel, Bernard, Tsimaratos, Michel, Loirat, Chantal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904385/ https://www.ncbi.nlm.nih.gov/pubmed/17216497 http://dx.doi.org/10.1007/s00467-006-0402-1 |
Ejemplares similares
-
Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations
por: Carrera, Fernando, et al.
Publicado: (2009) -
Quality of life in adolescents with chronic kidney disease who initiate haemodialysis treatment
por: Clavé, Stéphanie, et al.
Publicado: (2019) -
A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer
por: Smith, R E, et al.
Publicado: (2003) -
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002) -
Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes
por: Gabrilove, Janice, et al.
Publicado: (2008)